RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1

10 Oct, 2019 RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1

On October 10, 2019, we hosted an online RNAi Roundtable to review the progress with lumasiran, an RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1.

Access the replay

View the presentation

Read the transcript

• • Pritesh Gandhi, PharmD, Vice President, General Manager, Lumasiran
  • Elaine M. Worcester, M.D., Nephrologist & Professor of Medicine, University of Chicago Medicine
  • Andrew, Patient Diagnosed with Primary Hyperoxaluria Type 1
  • Nicole, Andrew’s Wife and Caregiver
  • Kenji Fujita, M.D., Vice President, Clinical Development